Purchase Order W9114F22P0054
Award Date
9/1/22
Potential Completion Date
8/31/23
Potential Value
$76K
Federal Agency
Medical Command
Awardee
Revvity Omics Inc.
Ultimate Awardee
Revvity Inc.
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Revvity Omics Inc., doing business as Perkinelmer Genetics, for newborn metabolic screening services. The contract, valued at $56,927.50, has an ultimate completion date of February 28, 2027. The contract was awarded without a small business set-aside designation. Perkinelmer Genetics, a subsidiary of Revvity Inc., specializes in providing comprehensive newborn screening testing services to federal government...
This is a firm fixed-price contract awarded by the U.S. Army Medical Command (MEDCOM) to Revvity Omics Inc., doing business as Perkinelmer Genetics, for $99,600.00. The contract is for newborn screening services, which involve testing infants for conditions such as galactosemia, hypothyroidism, sickle cell disease, and cystic fibrosis. Perkinelmer Genetics, a subsidiary of Revvity Inc., is the prime contractor and will perform the screening tests at its own laboratories. This contract does not...
This is a firm fixed price purchase order contract awarded by the Defense Health Agency to Revvity Omics Inc., doing business as Perkinelmer Genetics, for newborn screening services. The contract has a ceiling value of $371,000.00 and a period of performance from October 1, 2021 through September 30, 2024. Perkinelmer Genetics will provide screening of newborns for inherited metabolic disorders and other conditions, as recommended by the American College of Medical Genetics, for military...
This firm fixed-price purchase order was awarded by the Defense Health Agency to Revvity Omics Inc., doing business as Perkinelmer Genetics, for newborn screening services. The contract has a ceiling value of $165,711.65 and a period of performance from October 1, 2021 through September 30, 2026. Perkinelmer Genetics will provide first and second newborn screening tests for patients at the Weed Army Community Hospital in Fort Irwin, California. This contract is not set aside. Perkinelmer...
This federal contract award is for newborn screening testing services provided by Revvity Omics Inc., doing business as Perkinelmer Genetics, to the Defense Health Agency (DHA) for the Brian D. Allgood Army Community Hospital (BDAACH) in South Korea. The contract is a firm fixed price delivery order under a larger indefinite delivery, indefinite quantity (IDIQ) contract awarded to Perkinelmer Genetics in 2019 by the DHA to provide newborn screening for Army medical facilities in Korea. The...
This is a firm fixed price contract awarded by the U.S. Department of Defense's Medical Command (MEDCOM) to Revvity Omics Inc., doing business as Perkinelmer Genetics, for $91,840.00. The contract is for newborn screening services, which involves testing infants for conditions such as galactosemia, hypothyroidism, sickle cell disease, and cystic fibrosis. Perkinelmer Genetics is the prime contractor and does not appear to have any major subcontractors. This contract is not associated with a...
This contract was awarded by the U.S. Department of the Army Medical Command to Perkinelmer Genetics, Inc., a for-profit medical services provider, to conduct newborn screening testing. The contract has a firm fixed price of $148,000.00 and a completion date of September 30, 2020. Perkinelmer Genetics, a subsidiary of the parent company Revvity Inc., specializes in newborn and genetic screening services to support military hospitals and treatment facilities in the U.S. and overseas. This...
This is a firm fixed price contract awarded by the Medical Command (MEDCOM) of the U.S. Army to Revvity Omics Inc., doing business as Perkinelmer Genetics, for newborn screening services at the William Beaumont Army Medical Center in Fort Bliss, Texas. The contract has a ceiling value of $99,600.00 and a performance period through October 31, 2017. Perkinelmer Genetics is a subsidiary of the parent company Revvity Inc., which specializes in medical imaging and genetic testing products and...
The Department of the Army Medical Command awarded a Firm Fixed Price Blanket Purchase Agreement (BPA) call to Perkinelmer Genetics, Inc., a for-profit organization, to provide newborn screening tests. The contract has a potential value of $143,440.00 and a performance period ending on September 30, 2018. Perkinelmer Genetics, a subsidiary of Revvity Inc., specializes in newborn and genetic screening services, and has provided similar testing support to military hospitals and treatment...
This federal contract award to Revvity Omics Inc., doing business as Perkinelmer Genetics, is for $197,264 to provide newborn genetic screening services to the U.S. Air Force's Air Mobility Command. The firm fixed price purchase order has an ultimate completion date of August 9, 2028. Perkinelmer Genetics is a subsidiary of Revvity Inc., a for-profit organization specializing in medical imaging and genetic testing. This contract is not set aside. Perkinelmer Genetics has held numerous prior...